SCHEMBL6760699

SCHEMBL6760699

CCCCCN1CCC(=O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
ALDH2 P05091 1/20 0.50
ALDH3A1 P30838 1/20 0.50
CDC25A P30304 9/20 0.49
CES1 P23141 2/20 0.49
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
MITF O75030 1/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 2/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DRD2 P14416 1/20 0.41
DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5712077 0.84 ALDH1A1 (0.53) ALDH1A1ALDH2ALDH3A1CDC25ACES1
SCHEMBL9373300 0.80 KDM4E (0.39) ALDH1A1MAPTGAAKDM4EGRM5
SCHEMBL9370111 0.78 ALDH1A1 (0.40) ALDH1A1ALDH2ALDH3A1CDC25ACES1
SCHEMBL9370114 0.78 ALDH1A1 (0.40) ALDH1A1ALDH2ALDH3A1CDC25ACES1
SCHEMBL19949917 0.78 KDM4E (0.51) ALDH1A1ALDH2ALDH3A1CDC25ACES1
SCHEMBL6698921 0.78 ALDH1A1 (0.70) ALDH1A1NPC1RAB9AMEN1MAPT
SCHEMBL29531557 0.78 ALDH1A1 (0.70) ALDH1A1NPC1RAB9AMEN1MAPT
SCHEMBL25229724 0.76 ALDH1A1 (0.68) ALDH1A1NPC1RAB9AMEN1MAPT
SCHEMBL9549231 0.76 ALDH1A1 (0.68) ALDH1A1NPC1RAB9AMEN1MAPT
SCHEMBL15921493 0.76 ALDH1A1 (0.68) ALDH1A1NPC1RAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5077410-A Hypotensive agents, antiedemic agents and diuretics MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-12-31 US claimed
EP-0243982-B1 1-ACYL-2,3-DIHYDRO-4(1H)-QUINOLINONE-4-OXIME DERIVATIVE, PROCESS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND INTERMEDIATES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-04-17 EP claimed
WO-1987006580-A1 1-ACYL-2,3-DIHYDRO-4(1H)-QUINOLINONE-4-OXIME DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1987-11-05 WO claimed
EP-0243982-A1 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivative, process for the production thereof, pharmaceutical composition and intermediates MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1987-11-04 EP claimed
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
CN-1432001-A 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents UPJOHN CO (US) 2003-07-23 CN disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
EP-0315115-B1 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives, process for producing them and use thereof MOCHIDA PHARM CO LTD (JP) 1994-06-15 EP disclosed
US-5077410-A Hypotensive agents, antiedemic agents and diuretics MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-12-31 US disclosed
EP-0243982-B1 1-ACYL-2,3-DIHYDRO-4(1H)-QUINOLINONE-4-OXIME DERIVATIVE, PROCESS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND INTERMEDIATES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-04-17 EP disclosed
US-4968680-A HYPOTENSIVE, ANTIEDEMIC, DIURETIC MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1990-11-06 US disclosed
US-4839368-A DIURETICS, HYPOTENSIVE AGENTS, ANTIEDEMIC AGENTS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1989-06-13 US disclosed
EP-0315115-A2 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives, process for producing them and use thereof MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1989-05-10 EP disclosed
US-4816454-A CARDIOVASCULAR DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1989-03-28 US disclosed
WO-1987006580-A1 1-ACYL-2,3-DIHYDRO-4(1H)-QUINOLINONE-4-OXIME DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1987-11-05 WO disclosed
EP-0243982-A1 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivative, process for the production thereof, pharmaceutical composition and intermediates MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1987-11-04 EP disclosed
EP-0175363-A2 4,5-Dihydro-3(2H)-pyridazinones, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1986-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 ALDH1A1 668/4885ALDH2 2830/4885ALDH3A1 985/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L ALDH1A1 463/4885ALDH2 2348/4885ALDH3A1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.